在PM20D1-NADA通路保护对帕金森病的疾病
Yunying Yang1, Sichun Chen1, Li Zhang1
1Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cell death and differentiation
|August 22, 2024
概括
含有1 (PM20D1) 酶的peptidase M20域将多巴胺转化为N-arachidonoyl多巴胺 (NADA),这抑制了α-synuclein聚合. 这种途径可以防止帕金森病的病理和神经退行.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 帕金森病 (PD) 涉及多巴胺基神经元损失和α-synuclein (α-Syn) 聚合.
- 在PD中α-Syn聚合和神经退行的分子机制尚未完全理解.
- 位于与PD相关的PARK16位点中的PM20D1基因与PD风险有关.
研究的目的:
- 研究PM20D1在调节α-Syn病理中的作用.
- 阐明PM20D1影响α-Syn聚合和神经退行的机制.
- 在PD小鼠模型中评估PM20D1-NADA途径的治疗潜力.
主要方法:
- 生物化学测试以确定PM20D1酶活性和产品识别.
- 细胞和动物模型的synucleinopathy.
- 分析α-Syn聚合,酸化和多巴胺能神经退行.
- 行为测试用于评估小鼠的运动功能.
主要成果:
- PM20D1催化了多巴胺转化为N-阿拉基多诺伊尔多巴胺 (NADA).
- 纳达直接与α-Syn相互作用,抑制其聚合和酸化.
- 纳达调节TRPV4介导的流入,减少下游的酸酶活性.
- 随着年龄的增长,PM20D1的表达会下降.
- 在小鼠模型中,PM20D1过度表达或NADA的使用改善了α-Syn病理,神经退行和运动缺陷.
结论:
- PM20D1-NADA通路代表了一种新的机制,可以防止α-Syn病理.
- 纳达抑制α-Syn聚合和神经退行的能力为帕金森病提供了潜在的治疗策略.
- 针对PM20D1-NADA通路可能有助于缓解PD进展.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K